Defunct Company
Total Trials
23
As Lead Sponsor
22
As Collaborator
1
Total Enrollment
857
NCT04136873
A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia
Phase: Phase 1
Role: Lead Sponsor
Start: Oct 15, 2019
Completion: Jun 3, 2021
NCT04232878
A Single Ascending Dose Trial of CVL-936 in Healthy Subjects
Start: Dec 16, 2019
Completion: May 21, 2020
NCT04295642
A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease
Start: Jan 8, 2020
Completion: Jul 23, 2021
NCT04241393
An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects
Start: Feb 4, 2020
Completion: Nov 8, 2020
NCT04592536
A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects
Start: Oct 6, 2020
Completion: Dec 13, 2021
NCT04457310
A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia
Phase: Phase 2
Role: Collaborator
Start: Mar 2, 2021
Completion: Mar 22, 2024
NCT04787302
PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing
Start: Jun 1, 2021
Completion: Jul 14, 2023
NCT05138653
A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants
Start: Oct 18, 2021
Completion: Jan 23, 2023
NCT05123079
Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy Participants
Start: Nov 2, 2021
Completion: Dec 7, 2021
NCT05106309
Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants
Start: Dec 29, 2021
Completion: Feb 24, 2022
NCT05245539
Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia
Start: Jan 24, 2022
Completion: Nov 14, 2022
NCT05404529
To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function
Start: Apr 29, 2022
Completion: Jan 24, 2023
NCT05404542
To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function
Start: May 10, 2022
Completion: Aug 14, 2023
NCT05581823
Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants
Start: Oct 19, 2022
Completion: Feb 2, 2023
NCT05610189
Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease
Start: Dec 15, 2022
Completion: Dec 17, 2023
NCT05547542
Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing
Start: Mar 2, 2023
Completion: Aug 6, 2024
NCT05824143
Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants
Start: Apr 17, 2023
Completion: Jul 7, 2023
NCT05915546
The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult Participants
Start: Jun 8, 2023
Completion: Jul 26, 2023
NCT05933187
A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants
Start: Jul 19, 2023
Completion: Sep 12, 2023
NCT05965219
A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants
Start: Aug 15, 2023
Completion: Nov 10, 2023
NCT06301971
A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants
Start: Mar 4, 2024
Completion: Apr 4, 2024
NCT06366243
A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants
Start: May 10, 2024
Completion: Jun 20, 2024
NCT06435923
A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male Participants
Start: May 29, 2024
Completion: Jul 3, 2024